Science & Technology
Development of Small-Molecule Degraders of APP as the first-in-class drugs for Alzheimer's therapy
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41AG090241-01
Award Ceiling
$500K
Award Floor
$500K
Close Date
Aug 31, 2025
Total Funding
$500K
Expected Awards
1
Posted Date
Sep 1, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R41AG090241-01
Description
STTR Phase Phase I award: "Development of Small-Molecule Degraders of APP as the first-in-class drugs for Alzheimer's therapy" awarded to DEGROME THERAPEUTICS, INC. in INDIANAPOLIS, Indiana. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $499,883. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.